BARDA

BARDA

Biodefense Headlines – April 30, 2026

News Scan April 30, 2026

This week’s selections include cascading institutional disruptions reshaping U.S. public health and science governance — including the Trump administration’s mass firing of the National Science Board and restrictions on graduate…

Emergent BioSolutions Secures Rights to Pandemic Influenza Vaccine Candidate

Novartis Receives FDA Approval for First Cell-Culture Influenza Vaccine

Hurricane Sandy Impacts Biodefense, CBRN Conferences

NIAID Awards Funding for Non-Needle Anthrax Vaccine

BARDA Exercises Contract Option on Emergent BioSolutions Anthrax Vaccine

Dried Plasma Device for CBRNE Mass Casualty Scenario

New BARDA-Funded Influenza Diagnostic Launched

Cytori to Develop Cell Therapies for Radiation Injury Thermal Burns

Hertfordshire Receives BARDA Award for Mass Casualty Decon Studies

BARDA Announces CBRN Medical Countermeasures Conference

HHS Announces Pandemic Preparedness Contracts to Top Pharma

Ricin Vaccine Shows Positive Phase 1B Clinical Trial Results

BARDA Seeks Antitoxins for Treatment of Inhalational Anthrax

Army to Award Chemical Warfare Agent Research Contract to BBRI

BARDA Multi-BAA Pre-Proposal Conference for CBRN, Influenza Countermeasures

Emergent Biosolutions, Novartis, Texas A&M to Lead New Biodefense Centers

BARDA CBRN Medical Countermeasures Pre-Proposal Conference

SIGA Ordered to Share Biodefense Contract Profits with PharmAthene

BARDA Influenza Drug Awardee Biota Relocating to U.S.

FDA Scrutinizes Home Anthrax Kits

Biodefense Headlines – April 30, 2026